EGFR and metastatic colorectal cancer: Randomised trials in metastatic colorectal cancer have demonstrated that use of monoclonal antibodies directed against EGFR (HER-1), namely cetuximab and panitumumab, is associated with favourable outcomes in patients expressing the wild-type form of K-ras proto-oncogene (Siddiqui and Piperdi, 2009).